Navigation Links
JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells
Date:2/4/2008

NEW YORK, February 4, 2008 The Juvenile Diabetes Research Foundation (JDRF), the worlds largest charitable funder of type 1 diabetes research, announced today that it is partnering with Plureon Corporation, a biotechnology company based in Winston-Salem, N.C. that focuses on developing therapeutic applications of stem cells.

Through its Industry Discovery and Development Partnership Program, JDRF is providing $500,000 over two years of research funding aimed at developing an insulin-producing beta cell therapy product for the treatment of type 1 diabetes.

Plureon is exploring exciting alternatives to treat or cure diabetes by developing cell therapies to replace beta cells using adult stem cells as a source, said Julia Greenstein, Therapeutic Program Director for Replacement at JDRF. The results from this study may provide a new strategy to restore function of insulin-producing cells, creating a significant, positive clinical impact on patients with diabetes.

This award enables us to extend our research in the field of diabetes, said Hal Eason, founder and CEO of Plureon. By leveraging our existing technology and know-how across additional sources of stem cells, we hope to open new pathways towards a cure. We are grateful for JDRFs partnership in this pursuit.

The project plans to use Plureons technology platform to isolate adult stem cells from a type 1 diabetes patient and re-program them to generate fully functional pancreatic beta-cells. The objective is to return the re-programmed insulin-producing cells back into the patient in an autologous manner, i.e., without the need for immunosuppressive agents normally required for organ transplantation in this manner, the patients own transplanted cells will be capable of glucose-dependent insulin secretion and the restoration of normal blood sugar levels.

Plureon is the latest company to work with JDRF through its innovative Industry Discovery and Development Partnership program. Through the program, JDRF partners with pharmaceutical, biotech, and medical device businesses that seek to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications. To date, JDRF has 22 IDDP partners across a range of research areas, committing approximately $25 million in research funding.

Diabetes is a chronic, debilitating disease affecting every organ system. There are two major types of diabetes: type 1 and type 2. Type 1 diabetes is an autoimmune disease in which a persons pancreas stops producing insulin, a hormone that enables people to get energy from food. Type 1 diabetes usually strikes in childhood, adolescence, or young adulthood, but lasts a lifetime. People with type 1 diabetes must take multiple injections of insulin daily or continuous infusion of insulin through a pump just to survive. (Type 2 diabetes is a metabolic disorder in which a persons body still produces insulin but is unable to use it effectively.) Taking insulin does not cure any type of diabetes nor prevent the possibility of its eventual and devastating effects: kidney failure, blindness, nerve damage, amputation, heart attack, and stroke.


'/>"/>

Contact: Susan Sherman
ssherman@jdrf.org
212-479-7510
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related medicine news :

1. Sergeants(R) Pet Care Products Announces Cause Marketing Partnership With the National Wildlife Federation
2. Red Cross Partners with YeePay on China Snow Disaster Relief
3. Bobbi Brown Cosmetics Creates Limited-Edition Lip Palette in Partnership with The Heart Truths Red Dress Collection 2008 Fashion Show
4. HealthPartners Contracts with SEIU Healthcare Minnesota Expires with No Agreement on New Contracts
5. Bobbi Brown Cosmetics Creates Limited-Edition Red Lip Palette in Partnership With The Heart Truths 2008 Red Dress Collection
6. Helios Education Foundation Invests $6.5 Million in New Partnership with TGen
7. Abbey Spanier Rodd & Abrams, LLP Files Class Action Lawsuit on Behalf of Purchasers of American Dental Partners, Inc. Securities
8. MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers
9. Time Domain Adds Eleven Partners to its Channel Reseller Network of PLUS(TM) Ultra Wideband Solutions Providers
10. Arthur Patrick Partners Acquires Fit Fuel, LLC
11. Medical University of South Carolina (MUSC) and Halsey Institute Create Partnership Between Art and Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... 30, 2016 , ... "This plugin comes with 60 customizable ... CEO of Pixel Film Studios. , TransPack Volume 7 features over 60 ... abstract transitions to more simple wipes with blur & drop shadow options. Utilize ...
(Date:5/30/2016)... ... 30, 2016 , ... Another ER facility operated by First Choice Emergency ... Drive, Plano, TX and is open 24 hours daily. , First Choice Emergency Room ... open house. The Jasper High School band entertained attendees and accepted First Choice Emergency ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating web themed intros and ... of their project," said Christina Austin - CEO of Pixel Film Studios. , ... for use in Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users ...
(Date:5/28/2016)... ... ... May 26, 2016- In search of the K. Warriors, Shaolin Institute is ... Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West Interstate 65 ... by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is the 28th ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 According to a new market ... - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast ... U.S. was valued at US$ 5.89 Bn in 2014 and ... 2015 to 2023 to reach US$ 7.99 Bn in 2023. ... emerging needle free drug delivery devices and the market is ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/26/2016)... Massachusetts , May 26, 2016 ... (NGS) has matured into an essential life science tool ... and development applications. BCC Research reveals in its new ... a second growth phase, one powered by a range ... fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) ...
Breaking Medicine Technology: